Successful Pregnancy Possible for Stem Cell Transplant Recipients
By Elana Gotkine HealthDay Reporter
MONDAY, July 15, 2024 -- Successful pregnancies are feasible for female allogeneic hematopoietic cell transplant (alloHCT) recipients, with most pregnancies occurring spontaneously, according to a study published online July 15 in Blood.
Katja Sockel, M.D., from the Technical University Dresden in Germany, and colleagues examined pregnancy and birth rates in a contemporary cohort using data from the Germany Transplant Registry, focusing on adult women aged 18 to 40 years who underwent alloHCT between 2003 and 2018.
The researchers found that 50 of the 2,654 transplanted women experienced 74 pregnancies, occurring at a median of 4.7 years posttransplant; 57 of the pregnancies (77 percent) resulted in live births. Among HCT recipients, the annual first birth rate was 0.45 percent, more than six times lower than in the general population. At 10 years after HCT, the probability of a live birth was 3.4 percent. Younger age at alloHCT, nonmalignant transplant indications, no total body irradiation or a cumulative dose of <8 Gy, and nonmyeloablative/reduced-intensity conditioning were factors associated with an increased likelihood of pregnancy. Of the pregnancies, 72 percent occurred spontaneously, while assisted reproductive technologies were used in the remaining cases. Compared with the general population, preterm delivery and low birth weight were more common.
"Fertility counseling before HCT should be provided to every woman of childbearing age, not only to discuss fertility preservation techniques, but also to inform patients about the potential for natural fertility restoration after HCT to prevent unexpected pregnancies," the authors write.
One author disclosed financial ties to AbbVie, Medac, Novartis, and Takeda.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2024
Read this next
Out-of-Pocket Costs Considerable, Increasing for Prostate Cancer Diagnostic Testing
MONDAY, July 15, 2024 -- For patients with private insurance undergoing diagnostic testing after prostate-specific antigen (PSA)-based screening, out-of-pocket costs are...
Modifiable Risk Factors Account for Many Cancer Cases, Deaths
MONDAY, July 15, 2024 -- An estimated 40.0 percent of all incident cancer cases and 44.0 percent of cancer deaths are attributable to potentially modifiable risk factors among...
Continual Cuffless BP Monitoring Can Classify Time-in-Target-Range Accurately
FRIDAY, July 12, 2024 -- Continual cuffless blood pressure (BP) monitoring can classify time-in-target-range (TTR) accurately, according to a study published online June 26 in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.